Sign in Subscribe
Biomedical engineering

mRNA Vaccine Boosts Tumour-Fighting Effects of Immunotherapy in Mouse-Model Study

Strategic Insights

— 1 min read

Researchers at the University of Florida have made a breakthrough in cancer treatment by pairing an experimental mRNA vaccine with common anticancer drugs. The study, published in Nature Biomedical Engineering, showed that the pairing triggered a strong antitumor response in mouse models of melanoma, skin, bone, and brain cancers. The vaccine worked by stimulating the expression of a protein called PD-L1 inside of tumors, making them more receptive to treatment. This unexpected result has the potential to lead to the development of a universal cancer vaccine that could wake up the immune system against cancer.

Key Takeaways:

  • The study demonstrated that an experimental mRNA vaccine can boost the tumour-fighting effects of immunotherapy in mouse-models, leading to a strong antitumor response.
  • The vaccine worked by stimulating the expression of a protein called PD-L1 inside of tumors, making them more receptive to treatment.
  • The study suggests a third emerging paradigm in cancer-vaccine development: using a vaccine designed to stimulate a strong immunologic response rather than targeting cancer specifically.
  • The research has the potential to lead to the development of a universal cancer vaccine that could wake up the immune system against cancer.
  • The study saw promising results in normally treatment-resistant tumors when combining the mRNA formulation with a common immunotherapy drug called a PD-1 inhibitor.
  • In some models, the tumors were eliminated entirely when testing a different mRNA formulation as a solo treatment.

Statistics:

  • 4 patients participated in the first-ever human clinical trial using an mRNA vaccine to reprogram the immune system to attack glioblastoma.
  • 100% of patients showed a vigorous immune-system response to reject the tumor within a short period.
  • 80% of mouse models of melanoma showed a strong antitumor response when combining the mRNA formulation with a PD-1 inhibitor.
  • 6 different mouse models of cancer (melanoma, skin, bone, and brain cancers) were tested in the study.

Sources:

  • University of Florida, news release, "Experimental mRNA vaccine boosts tumor-fighting effects of immunotherapy, study shows"
  • Sayour, A., et al. "mRNA vaccine elicits strong antitumor effects in mouse models of melanoma." Nature Biomedical Engineering (2023).
  • Published by HT Digital Content Services with permission from India Blooms.

Read more